The users will get the sources and the permission to use those sources so they do not have to be powerless and dependent on the company's good will to provide patches. I can't imagine why this is a difficult concept to comprehend.
>You clarify that "customers should be allowed to get the derived software on the same generous terms as the company received the original on", but that assumes that the companies have customers. Very few companies that use academically produced bioinformatics software have downstream customers of that software.
Yes, if they have customers, no matter how few, those customers should have all the permissions associated with free software. I don't see the problem here. It's not an unreasonable assumption that a nonzero number bioinformatics companies have a nonzero number of customers.
>For the vast majority of companies that only use the software in-house, which is likely 99+% of all companies, how does using the GPL or any other free software license lead to the company repaying the favor? What's wrong for asking for payment in cash instead of other more nebulous contributions?
If nothing else, the burden of maintaining a private fork, and integrating upstream changes with your own, can be an incentive to just send your changes upstream.